# Monoclonal Antibody for Treatment of Inhalation Anthrax

> **NCT00138411** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 36 (—)

## Conditions studied

- Bacillus Anthracis (Anthrax)

## Interventions

- **DRUG:** Ciprofloxacin 500 mg
- **DRUG:** ETI-204 (Anthim)

## Key facts

- **NCT ID:** NCT00138411
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 36 (—)
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138411, "Monoclonal Antibody for Treatment of Inhalation Anthrax". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00138411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*